Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells

Poly(ADP-ribose) polymerase (PARP) are critical DNA repair enzymes that are activated as part of the DNA damage response (DDR). Although inhibitors of PARP (PARPi) have emerged as small molecule drugs and have shown promising therapeutic effects, PARPi used as single agents are clinically limited to...

Full description

Saved in:
Bibliographic Details
Main Authors: Yusoh, Nur Aininie, Chia, Suet Lin, Saad, Norazalina, Ahmad, Haslina, Gill, Martin R.
Format: Article
Published: Nature Publishing 2023
Online Access:http://psasir.upm.edu.my/id/eprint/109311/
https://www.nature.com/articles/s41598-023-28454-x?error=cookies_not_supported&code=76e60f36-2a34-427f-8afe-0a710119131a
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Putra Malaysia
id my.upm.eprints.109311
record_format eprints
spelling my.upm.eprints.1093112024-08-16T07:49:29Z http://psasir.upm.edu.my/id/eprint/109311/ Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells Yusoh, Nur Aininie Chia, Suet Lin Saad, Norazalina Ahmad, Haslina Gill, Martin R. Poly(ADP-ribose) polymerase (PARP) are critical DNA repair enzymes that are activated as part of the DNA damage response (DDR). Although inhibitors of PARP (PARPi) have emerged as small molecule drugs and have shown promising therapeutic effects, PARPi used as single agents are clinically limited to patients with mutations in germline breast cancer susceptibility gene (BRCA). Thus, novel PARPi combination strategies may expand their usage and combat drug resistance. In recent years, ruthenium polypyridyl complexes (RPCs) have emerged as promising anti-cancer candidates due to their attractive DNA binding properties and distinct mechanisms of action. Previously, we reported the rational combination of the RPC DNA replication inhibitor [Ru(dppz)<jats:sub>2</jats:sub>(PIP)]2+ (dppz = dipyrido[3,2-<jats:italic>a</jats:italic>:2′,3′-<jats:italic>c</jats:italic>]phenazine, PIP = 2-(phenyl)-imidazo[4,5-<jats:italic>f</jats:italic>][1,10]phenanthroline), “Ru-PIP”, with the PARPi Olaparib in breast cancer cells. Here, we expand upon this work and examine the combination of Ru-PIP with Olaparib for synergy in lung cancer cells, including in 3D lung cancer spheroids, to further elucidate mechanisms of synergy and additionally assess toxicity in a zebrafish embryo model. Compared to single agents alone, Ru-PIP and Olaparib synergy was observed in both A549 and H1975 lung cancer cell lines with mild impact on normal lung fibroblast MRC5 cells. Employing the A549 cell line, synergy was confirmed by loss in clonogenic potential and reduced migration properties. Mechanistic studies indicated that synergy is accompanied by increased double-strand break (DSB) DNA damage and reactive oxygen species (ROS) levels which subsequently lead to cell death via apoptosis. Moreover, the identified combination was successfully able to inhibit the growth of A549 lung cancer spheroids and acute zebrafish embryos toxicity studies revealed that this combination showed reduced toxicity compared to single-agent Ru-PIP. Nature Publishing 2023-01-26 Article PeerReviewed Yusoh, Nur Aininie and Chia, Suet Lin and Saad, Norazalina and Ahmad, Haslina and Gill, Martin R. (2023) Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells. Scientific Reports, 13. art. no. 1456. pp. 1-15. ISSN 2045-2322 https://www.nature.com/articles/s41598-023-28454-x?error=cookies_not_supported&code=76e60f36-2a34-427f-8afe-0a710119131a 10.1038/s41598-023-28454-x
institution Universiti Putra Malaysia
building UPM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Putra Malaysia
content_source UPM Institutional Repository
url_provider http://psasir.upm.edu.my/
description Poly(ADP-ribose) polymerase (PARP) are critical DNA repair enzymes that are activated as part of the DNA damage response (DDR). Although inhibitors of PARP (PARPi) have emerged as small molecule drugs and have shown promising therapeutic effects, PARPi used as single agents are clinically limited to patients with mutations in germline breast cancer susceptibility gene (BRCA). Thus, novel PARPi combination strategies may expand their usage and combat drug resistance. In recent years, ruthenium polypyridyl complexes (RPCs) have emerged as promising anti-cancer candidates due to their attractive DNA binding properties and distinct mechanisms of action. Previously, we reported the rational combination of the RPC DNA replication inhibitor [Ru(dppz)<jats:sub>2</jats:sub>(PIP)]2+ (dppz = dipyrido[3,2-<jats:italic>a</jats:italic>:2′,3′-<jats:italic>c</jats:italic>]phenazine, PIP = 2-(phenyl)-imidazo[4,5-<jats:italic>f</jats:italic>][1,10]phenanthroline), “Ru-PIP”, with the PARPi Olaparib in breast cancer cells. Here, we expand upon this work and examine the combination of Ru-PIP with Olaparib for synergy in lung cancer cells, including in 3D lung cancer spheroids, to further elucidate mechanisms of synergy and additionally assess toxicity in a zebrafish embryo model. Compared to single agents alone, Ru-PIP and Olaparib synergy was observed in both A549 and H1975 lung cancer cell lines with mild impact on normal lung fibroblast MRC5 cells. Employing the A549 cell line, synergy was confirmed by loss in clonogenic potential and reduced migration properties. Mechanistic studies indicated that synergy is accompanied by increased double-strand break (DSB) DNA damage and reactive oxygen species (ROS) levels which subsequently lead to cell death via apoptosis. Moreover, the identified combination was successfully able to inhibit the growth of A549 lung cancer spheroids and acute zebrafish embryos toxicity studies revealed that this combination showed reduced toxicity compared to single-agent Ru-PIP.
format Article
author Yusoh, Nur Aininie
Chia, Suet Lin
Saad, Norazalina
Ahmad, Haslina
Gill, Martin R.
spellingShingle Yusoh, Nur Aininie
Chia, Suet Lin
Saad, Norazalina
Ahmad, Haslina
Gill, Martin R.
Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
author_facet Yusoh, Nur Aininie
Chia, Suet Lin
Saad, Norazalina
Ahmad, Haslina
Gill, Martin R.
author_sort Yusoh, Nur Aininie
title Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
title_short Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
title_full Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
title_fullStr Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
title_full_unstemmed Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
title_sort synergy of ruthenium metallo-intercalator, [ru(dppz)2(pip)]2+, with parp inhibitor olaparib in non-small cell lung cancer cells
publisher Nature Publishing
publishDate 2023
url http://psasir.upm.edu.my/id/eprint/109311/
https://www.nature.com/articles/s41598-023-28454-x?error=cookies_not_supported&code=76e60f36-2a34-427f-8afe-0a710119131a
_version_ 1809142986634690560